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Abstract
 
The mechanisms by which immune responses to nonpathogenic environmental antigens lead
to either allergy or nonharmful immunity are unknown. Single allergen-specific T cells constitute
a very small fraction of the whole CD4
 
 
 
 T cell repertoire and can be isolated from the peripheral
blood of humans according to their cytokine profile. Freshly purified interferon-
 
 
 
–, interleukin
(IL)-4–, and IL-10–producing allergen-specific CD4
 
 
 
 T cells display characteristics of T helper
cell (Th)1-, Th2-, and T regulatory (Tr)1–like cells, respectively. Tr1 cells consistently represent
the dominant subset specific for common environmental allergens in healthy individuals; in
contrast, there is a high frequency of allergen-specific IL-4–secreting T cells in allergic individuals.
Tr1 cells use multiple suppressive mechanisms, IL-10 and TGF-
 
 
 
 as secreted cytokines, and
cytotoxic T lymphocyte antigen 4 and programmed death 1 as surface molecules. Healthy and
allergic individuals exhibit all three allergen-specific subsets in different proportions, indicating
that a change in the dominant subset may lead to allergy development or recovery. Accord-
ingly, blocking the suppressor activity of Tr1 cells or increasing Th2 cell frequency enhances
allergen-specific Th2 cell activation ex vivo. These results indicate that the balance between
allergen-specific Tr1 cells and Th2 cells may be decisive in the development of allergy.
Key words: peripheral tolerance • allergens • suppression • interleukins • immune regulation
 
Introduction
 
The immune system must distinguish between innocuous
and pathological antigens to prevent unnecessary and self-
destructive immune responses (1, 2). A central finding from
experimental models and human studies shows that allergic
diseases are due to an aberrant immune response mediated
through a key effector cell, the Th type 2 cell and an asso-
ciated cytokine pattern including IL-4, IL-5, and IL-13 (3,
4). Therefore, the most pronounced findings with potential
relevance to allergy therapy are related directly to the con-
trol of these Th2 immune effectors. There is strong evi-
dence that peripheral T cell regulation plays a crucial role
in the control of harmful T cell responses. To avoid
chronic cell activation and inflammation against nonpatho-
genic antigens through ingestion and inhalation, the immune
system has developed efficient peripheral tolerance mecha-
nisms. Since the early 1970s (5), different subtypes of regu-
latory and suppressor cells and mechanisms that may play a
role in peripheral tolerance have been demonstrated, and their
biology has been the subject of intensive investigation (6–14).
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A great deal of uncertainty remains about differentiation
factors, antigen specificity, and mechanisms of action of T
regulatory (Tr) cells. Several types of Tr cells have been
described with a unique mechanism of action that varies
depending on the experimental model. Recent studies
have shown that Tr cells act as suppressor T cells that
down-regulate other effector T cells and inflammation
models in chronic infection, organ transplantation, and au-
toimmunity (10, 15–17). Studies on the immune response
to allergens provide well-defined models for understanding
the regulation and circumvention of antigen-specific T cell
responses. The symptoms of IgE-mediated allergy rhinitis,
conjunctivitis, and asthma can be ameliorated by the tem-
porary suppression of mediators and immune cells (such as
antihistamines and corticosteroids; reference 18). How-
ever, the only long-term solution for the treatment of al-
lergy is allergen-specific immunotherapy by the adminis-
tration of high doses of allergen or allergen peptides that
specifically target T cells over a long period of time (19,
20). Successful venom and aeroallergen immunotherapy
was found to be associated with the induction of peripheral
tolerance in T cells by generation of Tr cells that secrete
the suppressive cytokines IL-10 and TGF-
 
 
 
, suggesting
that generation of Tr1 cells might play a role in healthy
immune response (11, 21).
Studies on immune response to allergens in healthy indi-
viduals demonstrated that a peripheral T cell repertoire to
allergens exists that recognizes the same T cell epitopes as
allergic patients (22, 23). In the present work, we used a di-
rect approach by purification, characterization, and fre-
quency determination of allergen-activated T cells accord-
ing to their cytokine secretion profile. This enabled a
suitable human model to investigate how harmless envi-
ronmental proteins are recognized and tolerated by the
immune system. We showed that healthy and allergic
immune response to common environmental proteins is
characterized by a delicate balance in frequency of allergen-
specific Tr1 cells and allergen-specific Th2 cells.
 
Materials and Methods
 
Study Population. 
 
Heparinized peripheral blood samples from
31 healthy individuals (mean age, 36 yr) with no history of atopy
and 8 birch pollen and 9 house dust mite allergic patients, who
were diagnosed by positive skin test reactivity and high specific
IgE antibodies (
 
 
 
0.70 kU/l, Pharmacia Cap assay) were studied.
Total IgE levels of healthy individuals were 
 
 
 
88 U/ml, and aller-
gic individuals were between 92 and 298 U/ml. The study was
approved by the ethical commission of Davos, Switzerland.
 
Antigens. 
 
rBet v 1 of birch pollen (
 
Betula verrucosa
 
), rDer p 1
of house dust mite (
 
Dermatophagoides pteronyssinus
 
), rPyr c 5 of
pear (
 
Pyrus communis
 
), and rCor a 1 of hazelnut (
 
Corylus avellana
 
)
were used. rPyr c 5 and r Cor a 1 were provided by S. Vieths
and D. Lüttkopf (Paul Ehrlich Institute, Langen, Germany). All
of the allergens did not contain detectable amounts of LPS and
were 
 
 
 
99% pure. Purified protein derivative of 
 
Mycobacterium
bovis
 
 (PPD) was obtained from the Serum Institute, Copen-
hagen, Denmark. Tetanus toxoid was obtained from the Insti-
tute Berne, Switzerland.
 
Purification of Allergen-specific IL-4–, IFN-
 
 
 
–, and IL-10–secreting
Cells. 
 
PBMCs were isolated by Ficoll (Biochrom) density gra-
dient centrifugation of peripheral venous blood, and cells were
washed three times and resuspended in RPMI 1640 medium sup-
plemented as described previously (8). 2.5 
 
 
 
 10
 
7
 
 cells were stim-
ulated with 0.3 
 
 
 
M antigens in 5 ml of medium in six-well plates
in duplicates (Costar Corp.). After 12 h of stimulation in humidi-
fied 5% CO
 
2
 
, cells were harvested and labeled with 50 
 
 
 
g/ml
anti–IFN-
 
 
 
/CD45, anti–IL-4/CD45, or anti–IL-10/CD45 Ab–
Ab conjugates (Miltenyi Biotec) for 10 min at a concentration of
10
 
8
 
 cells/ml in ice-cold RPMI 1640 medium (24). The cells
were diluted with 37
 
 
 
C warm medium to a final concentration of
10
 
6
 
 cells/ml and allowed to secrete and capture the respective cy-
tokines for 45 min at 37
 
 
 
C. After capturing the secreted cyto-
kines on their surface, cells were centrifuged at 300 
 
g
 
 for 5 min at
4
 
 
 
C and resuspended at a concentration of 10
 
8
 
 cells/ml in ice-
cold buffer containing 0.5% BSA and 5 mM EDTA (both ob-
tained from Sigma-Aldrich) in PBS. The cells were stained with 5
 
 
 
g/ml PE-conjugated anti–IFN-
 
 
 
, anti–IL-10, or anti–IL-4 for
10 min at 4
 
 
 
C. The cells were washed and resuspended in 400 
 
 
 
l
BSA-EDTA PBS and magnetically labeled for 15 min at 4
 
 
 
C
with 100 
 
 
 
l of anti-PE microbeads. After washing, labeled cells
were purified by immunomagnetic separation (AutoMacs; Mil-
tenyi Biotec). The cells were counterstained by FITC-labeled anti-
CD4 and anti-CD8 mAb (Immunotech) and analyzed in a flow
cytometer (Epics XL; Beckman Coulter; Fig. S1). The purity of
allergen-specific CD4
 
 
 
 cytokine-secreting cells was between 88
and 96%. The frequency of allergen-stimulated and unstimulated
cells was calculated by dividing the number of purified cytokine-
secreting CD4
 
 
 
 T cells by the initial number of CD4
 
 
 
 T cells.
To obtain the frequency of allergen-specific, cytokine-secreting
T cells, the unstimulated cytokine-secreting CD4
 
 
 
 T cell fre-
quency was subtracted from allergen-stimulated cell number.
 
T Cell Cultures. 
 
The purified allergen-specific, cytokine-
secreting T cells were used immediately or expanded in the pres-
ence of 1 nM doses of growth factors (IL-2 for IFN-
 
 
 
–secreting
T cells; IL-2 and IL-4 for IL-4-secreting T cells; and IL-2 and IL-
15 for IL-10–secreting T cells; Novartis AG). Their cytokine
profile was determined both immediately after purification and
after in vitro expansion. Expanded IL-4–, IL-10–, and IFN-
 
 
 
–
producing cells were washed, and 5 
 
 
 
 10
 
5
 
 cells were restimulated
with a combination of mAbs to CD2, CD3, and CD28 mole-
cules (each 0.5 
 
 
 
g/ml; CLB) in 500 
 
 
 
l supplemented RPMI
1640 medium in 48-well plates for 3 d in triplicates. Supernatants
were harvested, and cytokines were determined by solid phase
sandwich ELISAs for IFN-
 
 
 
, IL-4, IL-5, IL-10, IL-13, and TGF-
 
 
 
as described previously (8, 21). Anti–IL-4 and anti–IFN-
 
 
 
 mAbs
were provided by C.H. Heusser (Novartis Pharmaceuticals,
Basel, Switzerland).
Allergen-specific T cell proliferative response was determined
by stimulation of 2 
 
 
 
 10
 
5
 
 PBMCs alone or together with ex-
panded or freshly purified allergen-specific, cytokine-secreting T
cells for 5 d with 0.3 
 
 
 
M of antigens in 200 
 
 
 
l of medium in 96-
well flat-bottom tissue culture plates in triplicates (25). Autolo-
gous 3,000 rad irradiated PBMCs were used as APCs. Cells were
pulsed with 1 
 
 
 
Ci/well [
 
3
 
H]thymidine (Dupont and NEN Life
Science Products), and incorporation of labeled nucleotide was
determined after 8 h in an LKB 
 
 
 
 plate reader (Wallac and Amer-
sham Biosciences). For polyclonal activation of T cells, plates
were coated for 2 h at 37
 
 
 
C with 10 
 
 
 
g/ml anti-CD3. IL-10 was
neutralized in cultures with 4 
 
 
 
g/ml anti–IL-10R mAb (pro-
vided by K. Moore, DNAX Research Institute, Palo Alto, CA;
reference 26). TGF-
 
 
 
 was neutralized in cultures with 100 ng/ml 
Akdis et al.
 
1569
 
of recombinant human soluble TGF-
 
 
 
 receptor II/Fc chimeric
protein (R&D Systems; reference 21). Programmed death 1 (PD-1)
activity was neutralized in cultures with 5 
 
 
 
g/ml anti–human
PD-1 (Bioscience Insight Biotechnology Ltd.). CTL antigen 4
(CTLA-4) activity was neutralized with 5 
 
 
 
g/ml anti-CD152
F(ab)
 
2
 
 (Ancell and Qbiogene). The neutralizing activity of these
approaches was controlled in titrated doses. Rabbit IgG, rat IgG,
mouse IgG1, or BSA (Beckman Coulter) served as control.
 
Flow Cytometry, Immunohistology, and ELISPOT Assay. 
 
2.5 
 
 
 
10
 
4
 
 cells were stained with FITC-conjugated anti-CD25 mAb
together with anti–CD4-ECD, anti–CD152-PE (CTLA-4; BD
Biosciences), or anti–PD-1 (Bioscience Insight Biotechnology
Ltd.) for 30 min at 4
 
 
 
C. Stained cells were fixed in 2% parafor-
maldehyde. The controls were FITC, PE, or ECD-conjugated
mouse IgG1. For analysis of IL-10R, 5 
 
 
 
 10
 
4
 
 cells were stained
with 50 
 
 
 
g/ml of anti–IL-10
 
 
 
 mAb (DNAX Research Institute)
for 30 min and washed with 2% FCS containing PBS. FITC-
conjugated anti–rat Ig was the second Ab used for 30 min.
Intracellular cytokines were detected after anti-CD2, anti-
CD3, and anti-CD28 mAb stimulation for 12 h. 2 
 
 
 
M monensin
(Sigma-Aldrich) was added during the last 10 h (11). Intracyto-
plasmic cytokine profile of in vitro–expanded allergen-specific T
cells was determined as aforementioned. Labeled mAbs for cyto-
kines were obtained from BD Biosciences. Immune histology
was performed in cytospins of freshly purified cells by using anti–
human TGF-
 
 
 
RI, anti–human TGF-
 
 
 
RII, or rabbit IgG as iso-
type control (all obtained from Santa Cruz Biotechnology Inc.) as
described previously (27).
10
 
6
 
 cells/ml PBMCs from six healthy donors were stimulated
in 200 
 
 
 
l of medium 96-well flat bottom ELISPOT plates for
18 h (Euroclone Ltd.). Locally produced IL-4, IFN-
 
 
 
, and IL-10
were captured by specific mAb. After cell lysis, trapped cytokine
molecules were revealed by a secondary biotinylated detection an-
tibody, which is in turn recognized by streptavidin conjugated to
alkaline phosphatase. Colored “purple” spots developed after sub-
strate addition were determined (ImmunoSpot; Cellular Technol-
ogy Ltd.). The number of spots determined in triplicates of un-
stimulated wells was subtracted from 0.3 
 
 
 
M Der p 1–stimulated
wells. 18 h was found to be the optimal time for the determina-
tion of frequency of cytokine-secreting cells, as it is the time point
for highest cytokine secretion before T cell proliferation starts.
 
Quantitative Real-Time PCR. 
 
Immediately after purifica-
tion, antigen-specific, cytokine-secreting T cells were lysed with
RNeasy lysis buffer, and the RNA was isolated using the RNeasy
mini kit (QIAGEN) and eluted in 30 
 
 
 
l ddH
 
2
 
O. Reverse tran-
scription was performed with TaqMan
 
®
 
 reverse transcription re-
agents with random hexamers (Applied Biosystems). The PCR
primers and probes detecting elongation factor-1
 
 
 
 (EF-1
 
 
 
), IL-
10, TGF-
 
 
 
, IL-13, and IFN-
 
 
 
 were designed based on sequences
reported in GenBank. Primers used were as follows: EF-1
 
 
 
 for-
ward primer, 5
 
 
 
-CTGAACCATCCAGGCCAAAT-3
 
 
 
, EF-1
 
 
reverse primer, 5 -GCCGTGTGGCAATCCAAT3 ; IL-13 for-
ward primer A, 5 -GCCCTGGAATCCCTGATCA-3 , IL-13
reverse primer A, 5 -GCTCAGCATCCTCTGGGTCTT-3 ;
IFN-  forward primer B, 5 -TCTCGGAAACGATGAAAT-
ATACAAGTTAT-3 , IFN-  reverse primer B, 5 -GTAACA-
GCCAAGAGAACCCAAAA-3 ; IL-10 forward primer, 5 -
GGCGCTGTCATCGATTTCTT-3 , IL-10 reverse primer, 5 -
TTGGAGCTTATTAAAGGCATTCTTC-3 ; TGF- 1 forward
primer, 5 -AAATTGAGGGCTTTCGCCTTA-3 , and TGF- 1
reverse primer, 5 -GAACCCGTTGATGTCCACTTG-3 . cDNAs
were amplified using SYBR®-PCR mastermix (Applied Bio-
systems) according to the recommendations of the manufacturer
in a total volume of 25  l in a sequence detection system (ABI
Figure 1. Allergen-specific IL-4-, IFN- –, and IL-10–
secreting T cells represent Th2-, Th1-, and Tr1-like
cells. (A) IL-10, IL-13, IFN- , and TGF-  mRNA
were quantified by real-time PCR immediately after
isolation of Der p 1– or Bet v 1–specific, cytokine-
secreting T cells and their relative expression compared
with the housekeeping gene EF-1 . The same results
were obtained in three independent experiments. (B) Bet
v 1–, Der p 1–, and Cor a 1–specific IL-4–, IFN- –,
and IL-10–secreting T cells (one allergic and one
healthy donor each; closed symbols, allergic donors;
open symbols, healthy donors) were in vitro expanded
for 2 wk, and their cytokine profile was determined in
supernatants by ELISA 72 h after anti-CD2, anti-CD3,
and anti-CD28 mAb stimulation. (C) Intracytoplasmic
cytokine profile of in vitro–expanded allergen-specific
T cells (the same results were obtained in 10 additional
experiments). Percentage of positive cells is shown in
each quadrant.Tr1/Th2 Cell Balance in Health and Allergy 1570
PRISM 7000; Applied Biosystems). Relative quantification was
performed as described previously (28). All amplifications were
performed in duplicates.
Statistical Interpretation.  Data are expressed as mean   SEM.
Student’s t test, Z test, and Mann-Whitney U test were used for
statistical analysis.
Online Supplemental Material.  Fig. S1 contains sample data of
the purification and frequency calculation of allergen-specific
CD4  cells according to their cytokine profile. Details of flow
cytometric analysis are shown, from allergen stimulation to fre-
quency calculation of purified IL-10–secreting Tr1 cells. Online
supplemental material is available at http://www.jem.org/cgi/
content/full/jem.20032058/DC1.
Results
Allergen-specific IL-4–, IFN- –, and IL-10–secreting T Cells
Represent Th2-, Th1-, and Tr1-like Cells.  To investigate
the regulation of specific immune response against environ-
mental protein antigens, we isolated CD4  T cells specific
to several food and aeroallergens from healthy and allergic
individuals according to their IL-4, IFN- , and IL-10 secre-
tion profile (Fig. S1, available at http://www.jem.org/cgi/
content/full/jem.20032058/DC1). To confirm their cyto-
kine profile, mRNA of IL-10, IL-13, IFN- , and TGF- 
were quantified immediately after isolation (Fig. 1 A). Re-
lative to the housekeeping gene EF-1 , IL-10–secret-
ing T cells expressed significantly high IL-10 mRNA and
IFN- –secreting T cells expressed significantly high IFN- 
mRNA. IL-13 mRNA was dominant in IL-4–secreting T
cells. Quantification of cytokines after in vitro expansion of
IL-4–, IL-10–, and IFN- –secreting T cells revealed that
these subsets contain Th2-like (IL-4, IL-5, and IL-13 high),
Th1-like (IFN-  high), and Tr1-like (IL-10 and TGF- 
high) cells, respectively (all P    0.0001 compared with
other subsets; Fig. 1, B and C). In addition, all three puri-
fied subsets consisted of some Th0 cells, which secrete both
Th1 and Th2 cytokines as well as IL-10 and TGF- . There
was no difference in cytokine profile at the single T cell
subset level between allergic and healthy individuals.
The antigen specificity of purified cytokine-secreting T
cells was studied by stimulation with the allergen that was
originally used for stimulation before purification and sev-
eral control antigens in the presence of autologous APCs.
Consistently, IL-10–secreting T cells showed very little or
no allergen-induced proliferation (Fig. 2 A). The prolifera-
tive response of allergen-specific IL-4– and IFN- –secret-
ing T cells was significantly high compared with IL-10–
Figure 2. Specificity and growth requirements of purified allergen-
specific T cells. (A) Bet v 1–, Der p 1–, and Cor a 1–specific IL-4–,
IFN- –, and IL-10–secreting T cells (one allergic and one healthy
donor each; closed symbols, allergic donors; open symbols,
healthy donors) were purified and in vitro expanded, and 5   105
cells were cocultured with 5   105 autologous irradiated PBMCs
as an APC source in the presence of the same antigen. [3H]Thymi-
dine incorporation (TdR) was determined after 5 d. *, P   0.001.
(B) Purified Bet v 1–specific and Der p 1–specific T cells did not
show any proliferative response to different control antigens (two
representative of six experiments are shown; mean   SD of triplicate
cultures). TT, tetanus toxoid; us, unstimulated. (C) Growth factor
requirements of antigen-specific IL-10–secreting T cells. After purifi-
cation, Bet v 1– or Der p 1–specific IL-10–secreting T cells were
first expanded for 10 d in the presence of IL-2, washed, and cultured
(5   104 cells) with 1-nM doses of different cytokines. [3H]Thy-
midine incorporation was determined after 3 d (mean   SD of
three independent experiments are shown).
Figure 3. Increased frequency of allergen-specific Tr1 cells in healthy
individuals and Th2 cells in allergic individuals. (A) Frequency of Der p 1–
and Bet v 1–specific, cytokine-secreting CD4  T cells from eight allergic
individuals and Cor a 1–, Bet v 1-, Der p 1–, and Pyr c 5–specific, cytokine-
secreting CD4  T cells from 15 healthy individuals out of pollen season.
(B) Frequency of Der p 1–specific T cells in six allergic and six healthy,
and Bet v 1–specific T cells in three allergic and three healthy individuals
by ELISPOT assay. *, P   0.01; **, P   0.001.Akdis et al. 1571
secreting T cells. There was no difference between different
allergens. T cells purified by certain antigen stimulation did
not show any cross-reactivity against control antigens (Fig. 2
B). All three subsets purified by Bet v 1 stimulation re-
sponded to Bet v 1, but not to tetanus toxoid and Der p 1.
Similarly, Der p 1–specific T cell subsets showed prolifera-
tive response to Der p 1, but not to tetanus toxoid and Bet v
1 as control antigens. Although they did not proliferate by
antigen stimulation, IL-10–secreting T cells used IL-2, IL-4,
IL-7, and IL-15 as growth factors and showed significant
proliferation (Fig. 2 C). Together with the quantitative cy-
tokine mRNA profiles of freshly purified cells, these data
demonstrate that allergen-specific Tr1-, Th1-, and Th2-like
cells can be purified from human peripheral blood.
Balance between Allergen-specific Tr1 Cells and Th2 Cells
Characterizes Healthy and Allergic Immune Response.  As it
was possible to purify single allergen-specific Th1-, Th2-,
and Tr1-like cells, their frequency and functional proper-
ties were investigated in the next step. The frequency of T
cell subsets specific to different mucosal allergens was com-
pared in healthy and allergic individuals using two different
techniques. Recombinant major allergens of house dust
mite (Der p 1) and birch pollen (Bet v 1) were used as
aeroallergens, and pear (Pyr c 5) and hazelnut (Cor a 1)
were used as food antigens to analyze the frequency of spe-
cific Th1-, Th2-, and Tr1-like cells. Although specific T
cells that belong to all three subsets were detectable in both
healthy and allergic individuals, allergen-specific IL-10–
secreting T cells were the predominant subset in healthy
individuals. We found similar results for each allergen. In
contrast, an increased frequency of IL-4–secreting T cells
was observed in allergic patients (Fig. 3 A). ELISPOT was
used as an alternative method in allergen-stimulated PBMC
cultures and demonstrated a similar frequency distribution
of Der p 1– and Bet v 1–specific T cell subsets (Fig. 3 B).
As aforementioned, all three subsets of single allergen-spe-
cific T cells are present in both healthy and allergic individu-
als. Accordingly, their role on allergen-induced T cell prolif-
eration and whether this is influenced by changing their
ratios was investigated. We assayed the allergen-induced
proliferation of IL-4– and IL-10–secreting T cells by adding
those purified cells back into autologous PBMCs. First, the
antigen-specific suppressor effect of IL-10–secreting T cells
was analyzed (Fig. 4 A). Bet v 1– and Der p 1–specific IL-4–
and IL-10–secreting T cells were separately purified from the
same healthy individuals. Their frequency was increased up
to 10 times higher than initial levels in PBMCs. PBMCs
alone did not show allergen-induced T cell proliferation,
which was achieved by increasing the numbers of allergen-
specific IL-4–secreting T cells. Der p 1–specific IL-10–
Figure 4. Antigen-specific suppression by Tr1 cells. (A) Der p
1–specific and Bet v 1–specific IL-4–secreting and IL-10–secreting
T cells were purified from healthy individuals. Their frequency was
calculated in CD4  T cells, and 2   105 PBMCs were immediately
reconstituted by increasing their frequency by 10 times (IL-4–
secreting T cells, 0.02–0.2%; IL-10–secreting T cells, 0.05–0.5%).
Cells were stimulated with the respective antigens and PPD. (B) Der
p 1–specific IL-4–secreting and IL-10–secreting T cells were purified
and in vitro expanded by IL-2/IL-4 and IL-2/IL-15, respectively.
2   105 PBMCs were enriched with 1,000 Der p 1–specific IL-4–
or IL-10–secreting T cells or their combinations in IL-4–secreting/
IL-10–secreting T cell ratios 1,000/1,000 (1:1), 1,000/500 (2:1),
1,000:250 (4:1), and 1,000:125 (8:1). Cells were stimulated with
0.3  M Der p 1 or 1  g/ml PPD. Der p 1–specific, IL-10–secreting
T cells added to PPD-stimulated PBMC cultures at indicated
numbers did not show any suppression. (C) The same experimental
design as in A was used, and cells were stimulated with both Der p 1
and Bet v 1 (0.3  M each). (A–C) [3H]Thymidine incorporation was
determined after 5 d. The same results were obtained in three
other experiments. *, P   0.001. (D) 105 PBMCs were stimulated
with anti-CD3 in the presence of different amounts of IL-10–
secreting and IL-4-secreting T cells. [3H]Thymidine incorporation
was determined after 3 d. Data represent two different experi-
ments. *, P   0.01.Tr1/Th2 Cell Balance in Health and Allergy 1572
secreting T cells only suppressed Der p 1–stimulated, but not
Bet v 1– or PPD-stimulated proliferation. Similarly, Bet v
1–specific IL-10–secreting T cells only suppressed Bet v
1–stimulated, but not Der p 1– or PPD-stimulated prolifera-
tion. There was no cross-suppression of Der p 1–specific IL-
10–secreting cells on Bet v 1 stimulation and Bet v 1–specific
IL-10–secreting T cells on Der p 1 stimulation, as well as
both IL-10–secreting T cells on PPD stimulation.
The retention of suppressive activity of Tr1 cells after
expansion ex vivo is obviously an absolute prerequisite for
usage in a possible cellular therapeutic approach. We tested
whether in vitro–expanded IL-10–secreting T cells main-
tain their suppressive activity. PBMCs of healthy individu-
als showed no or very limited proliferative response to Der
p 1. The addition of in vitro–expanded Der p 1–specific
IL-4, but not IL-10–secreting T cells significantly enhanced
Der p 1–induced proliferation (Fig. 4 B). Increased num-
bers of in vitro–expanded IL-10–secreting T cells signifi-
cantly suppressed IL-4–secreting T cell–mediated prolifera-
tion in Der p 1–stimulated PBMCs. A 1:1 ratio of effector
(IL-4–secreting) to suppressor (IL-10–secreting) T cells was
required for full suppression of T cell proliferation. In con-
trast, PPD-stimulated proliferation was not suppressed by
Der p 1–specific IL-10–secreting T cells.
To test whether the IL-10–secreting T cells induce by-
stander suppression on other T cells in their vicinity, we
cultured Der p 1–specific, IL-4–secreting cells with freshly
purified Der p 1– or Bet v 1–specific IL-10–secreting cells
in the presence of both Der p 1 and Bet v 1 (Fig. 4 C). Der
p 1–specific, IL-4–secreting T cell proliferation was sup-
pressed by Der p 1–, but not Bet v 1–specific Tr1 cells. As
few as 1,000 Tr1 cells were able to induce antigen-specific
suppression in 200,000 PBMCs. High numbers of freshly
purified Tr1 cells (at least 20,000 in 100,000 PBMCs) re-
sulted in a nonspecific suppressive activity on anti-CD3–
stimulated T cells (Fig. 4 D). In comparison, IL-4–secreting
T cells did not exert any suppressive effect on anti-CD3
stimulation. These data demonstrate allergen-specific sup-
pressor activity of Tr1 cells and the importance of the bal-
ance between allergen-specific Th2 and Tr1 cells for aller-
gen-induced T cell activation.
Allergen-specific Tr1 Cells Use Multiple Suppressor Factors.
Molecules that may play a role on suppressive mechanisms
of allergen-specific IL-10–secreting T cells were analyzed
Figure 5. Expression of suppressor molecules on IL-10–secreting T
cells. (A) Immediately after purification, antigen-specific IL-10–secreting
T cells of healthy individuals were analyzed for intracytoplasmic IL-10,
surface IL-10R, CTLA-4, CD25, and PD-1 by flow cytometry. Data are
compared with CD3  T cells of the same donor stimulated with the same
antigen. (B) TGF-  RI and RII expression by immunohistology. (A and
B) Same results were obtained in three independent experiments.
Figure 6. Multiple suppressive mechanisms play a role in peripheral
allergen tolerance. (A) Endogenous IL-10, TGF- , or both as well as
CTLA-4, PD-1, or both were neutralized in Der p 1–stimulated PBMCs
of healthy individuals. [3H]Thymidine incorporation (TdR), IFN- , and
IL-13 were determined at day 5. (B) Der p 1–specific proliferation of
PBMCs from house dust mite allergic patients was suppressed by 10 times
increased frequency of Der p 1–specific, IL-10–secreting T cells (IL-10 ).
The activity of IL-10, TGF- , CTLA-4, and PD-1 were neutralized.
[3H]Thymidine incorporation (TdR), IFN- , and IL-13 were deter-
mined at day 5. (control) Isotype control antibody. (A and B) Same results
were obtained in four independent experiments (two Bet v1 and two Der
p 1) all performed with freshly purified cells without in vitro expansion.
Bet v 1 stimulation in birch pollen–allergic individuals gave similar results.
All of the neutralization experiments were significantly different from the
control and IL-10–secreting T cell–suppressed condition at 0.3  M aller-
gen doses. P   0.001.Akdis et al. 1573
on freshly purified cells (Fig. 5). IL-10–secreting T cells
expressed high amounts of IL-10, IL-10R  chain, TGF- 
receptors I and II, CTLA-4, CD25, and PD-1, suggesting
that multiple suppressor factors may play a role on sup-
pression of allergen-specific Th2 cells by Tr1 cells in
healthy individuals.
Neutralization experiments revealed that all four sup-
pressive mechanisms may play a role in suppression of aller-
gen-specific Th2 cells. Der p 1– or Bet v 1–stimulated
PBMCs of healthy individuals did not show any T cell pro-
liferation. In both cases, neutralization of IL-10 and TGF- 
activity significantly enhanced antigen-induced prolif-
eration as well as IL-13 and IFN-  production (Fig. 6 A).
In addition, two other mechanisms apparently function
in healthy immune response to allergens because neutral-
ization of CTLA-4 or PD-1 significantly enhanced T cell
proliferation and IFN-  and IL-13 secretion in healthy in-
dividuals. In allergic individuals, Der p 1–induced T cell
proliferation was significantly high in PBMCs of house dust
mite allergic donors. A very clear suppression was achieved
by increasing the frequency of Der p 1–specific, IL-10–
secreting T cells. This suppression was partially inhibited by
blocking of IL-10R, TGF- , CTLA-4, or PD-1 (Fig. 6 B).
In these experiments, IL-10R–blocking mAbs may block
IL-10R on the APCs as well as on Tr1 cells; in addition,
TGF-  secreted from both Tr1 cells and APCs can be neu-
tralized by sTGF- R. CTLA-4 and PD-1 are blocked par-
ticularly on the surface of Tr1 cells. These data demonstrate
that IL-10, TGF- , CTLA-4, and PD-1 cooperate in the
suppression of immune response to allergens.
Discussion
The present work demonstrates that immune response to
allergens in health and disease is the result of a balance be-
tween allergen-specific Tr1 cells and allergen-specific Th2
cells. Active regulation has emerged as a very essential
mechanism for both inducing and equally importantly
maintaining specific immunological nonresponsiveness. By
analyzing Tr1 cells specific to various food or inhalant anti-
gens, we demonstrated that similar mechanisms take place in
healthy immune response to mucosal allergens. The IL-10–
secreting allergen-specific T cells represented the predomi-
nant subset with significantly high frequency in comparison
to IL-4– and IFN- –secreting T cells in healthy individuals.
Both ELISPOT for cytokines and purification of cytokine-
secreting T cells gave similar frequency numbers. Mecha-
nisms that control the in vivo shift between allergen-specific
T cell subsets remain to be elucidated. It can be hypothe-
sized that a switch in cytokine profile and apoptosis of effec-
tor T cells may play a role in the generation of an atopic
phenotype (29, 30). The stability of cytokine profile in dif-
ferentiated effector and memory T cell subsets in humans is
not fully known, and recent studies have demonstrated that
lineage-committed memory T cell subsets are responsive to
cytokine signals of the opposing lineage (30, 31). In addi-
tion, Tr1 cells do not appear to be anergic and may effi-
ciently expand in vivo (32) as they are shown to proliferate
by IL-2, IL-4, IL-7, and IL-15 in the present work.
There is clear evidence from various animal models and
human studies for an active mechanism of immune sup-
pression, whereby a distinct subset of T cells inhibits the
activation of conventional T cells in the periphery (7, 13,
14, 33). This Tr cell population has been determined as
CD4 CD25  T cells. They can prevent the development
of autoimmunity, indicating that the normal immune sys-
tem contains a population of professional regulatory T cells.
Elimination of CD4 CD25  T cells leads to spontaneous
development of various autoimmune diseases, such as gas-
tritis or thyroiditis, in genetically susceptible hosts. The fre-
quency of CD4 CD25  Tr cells is  10–15% of CD4  T
cells, whereas the frequency of IL-10–secreting T cells of a
single allergen specificity ranges between 0.1 and 0.007% of
CD4  T cells. This shows that the frequency of single al-
lergen-specific Tr1 cells, which are also CD4  CD25 ,
ranges between 1 in 1,000 and 1 in 20,000 of the whole
CD4  CD25  Tr cell population.
Although many aspects of the mechanisms by which
suppressor cells exert their effects remain to be elucidated,
it is well established that Tr cells suppress immune re-
sponses via cell-to-cell interactions and/or the production
of IL-10 and TGF-  (10, 11, 34, 35). Tr1 cells specific for
a variety of antigens arise in vivo, but may also differentiate
from naive CD4  T cells in the presence of IL-10 in vitro
(36). The nonspecific T cell suppressor activity of IL-10
and TGF-  has been consistently reported in experiments
with high amounts of exogenously added suppressor cyto-
kines (21, 25). However, the present work demonstrates
that Tr1 cells display antigen-specific suppressor activity in
very low numbers. If the number of cells exceed a thresh-
old that provides sufficient quantities of suppressor signals,
apparently they show nonspecific suppression. Depending
on their frequency, the first T cell that contacts the APC
may be very critical in the subsequent decision to stimulate
or suppress the specific immune response. If the first T cell
to contact the APC is a Tr1 cell, it may silence or regulate
the maturation of APC. IL-10 down-regulates the antigen-
presenting capacity, such as HLA-DR expression, costimu-
latory molecules, and several cytokines in dendritic cells
and monocytes/macrophages (37). Recently, differentia-
tion of a distinct dendritic cell subset in the presence of IL-
10 has been demonstrated that induces tolerance through
the generation of Tr1 cells (38). In addition, exposure of
mature pulmonary dendritic cells to respiratory allergens
stimulated the development of Tr1-like cells, which was
dependent on dendritic cell IL-10 production (39). To-
gether, these findings suggest that IL-10–secreting T cells
may regulate the functional state of APCs in a way that
these APCs can now promote the generation of Tr1 cells.
CD4 CD25  T cells are the only lymphocyte subpopu-
lation in mice and humans that express CTLA-4 constitu-
tively. The expression apparently correlates with the sup-
pressor function of CTLA-4. As demonstrated in the
present work, the blocking of CTLA-4 activity of Tr1 cellsTr1/Th2 Cell Balance in Health and Allergy 1574
reverses suppression in cocultures of CD4 CD25  and
CD4 CD25  T cells (40). Similarly, the treatment of mice
that were recipients of CD4 CD45RBlow T cells with
CTLA-4–blocking agents, abrogated the suppression of in-
flammatory bowel disease (41). These studies indicate that
signals that result from the engagement of CTLA-4 by its
ligands, CD80 or CD86, are required for the induction of
suppressor activity. Under some circumstances, the en-
gagement of CTLA-4 on the CD4 CD25  T cells by an-
tibody or by CD80/CD86 might lead to inhibition of the
TCR-derived signals that are required for the induction of
suppressor activity.
A subset of human Tr1 cells expressed functional PD-1
in the present work. PD-1 is an immunoreceptor tyrosine-
based inhibitory motif–containing receptor expressed upon
T cell activation. PD-1–deleted mice develop autoimmune
diseases, suggesting an inhibitory role for PD-1 in immune
responses (42). Members of the B7 family, PD-ligand (L)1
and PD-L2, are ligands for PD-1. PD-1/PD-L engagement
on murine CD4 and CD8 T cells results in inhibition of
proliferation and cytokine production. T cells stimulated
with anti-CD3/PD-L1Fc-coated beads display dramatically
decreased proliferation and IL-2 production (43).
Collectively, our results indicate that the control of Th2
immune response against naturally exposed harmless envi-
ronmental antigens is mediated by Tr1 cells in humans. Ef-
fector (allergen-specific Th2) and suppressor (allergen-
specific Tr1) T cells exist in both healthy and allergic indi-
viduals in certain amounts. Their ratio determines the de-
velopment of a healthy or an allergic immune response.
These data may explain the spontaneous development and
spontaneous healing of allergic diseases. Although in low
frequency, the existence of potential suppressive allergen-
specific Tr1 cells in allergic individuals suggests a possible
way of treatment. The knowledge of this cellular and mo-
lecular basis is pivotal in understanding the mechanisms of
immune tolerance or allergy development against harmless
environmental proteins.
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